Tesamorelin and Ipamorelin Research

Laboratory research on Tesamorelin and Ipamorelin reveals complementary mechanisms affecting growth hormone pathways. While each peptide stimulates GH release through different receptor interactions, their combined effects may extend beyond simple hormone elevation.

Current research demonstrates their individual influences on visceral fat reduction, muscle preservation, gastrointestinal function, and bone metabolism.

Effects on Growth Hormone Release

Tesamorelin is a GHRH analog that has been shown to augment basal and pulsatile GH secretion. It significantly increases IGF-1 levels. A study involving healthy subjects showed that tesamorelin treatment increased mean overnight GH, average log(10) GH peak area, and basal GH secretion¹.

Ipamorelin is a pentapeptide with distinct GH-releasing properties. It mimics ghrelin and binds to the ghrelin receptor (GHSR) in the brain, selectively stimulating GH release from the pituitary gland, which increases plasma GH levels. Ipamorelin’s GH release selectivity is similar to that of GHRH².

Lipolysis

Tesamorelin has demonstrated efficacy in reducing visceral adipose tissue (VAT) in HIV patients with lipodystrophy³. Studies have shown significant declines in VAT, hepatic fat, and trunk-to-appendicular fat ratio with tesamorelin treatment. It also reduces liver fat and improves liver enzymes⁴.

Ipamorelin stimulates appetite and enhances gastric motility. Research indicates it accelerates gastrointestinal transit and may ameliorate symptoms of postoperative ileus. In a rodent model, repetitive dosing of ipamorelin increased fecal pellet output, food intake, and body weight gain⁵.

Muscle Growth

Tesamorelin can increase skeletal muscle area and density. Among individuals with a clinically significant decrease in visceral adipose tissue, tesamorelin was effective in increasing the density of truncal muscle groups and the total area of the rectus and psoas muscles⁶.

In an adult rat model, ipamorelin counteracted the catabolic effects of glucocorticoids on skeletal muscles. Simultaneous administration of ipamorelin with glucocorticoids increased the maximum tetanic tension of calf muscles⁷.

Bone Density

Ipamorelin has been shown to increase bone mineral content (BMC) in young adult female rats. However, when corrected for body weight, total BMC was unaffected. The increase in cortical BMC was attributed to increased cross-sectional bone area, while cortical volumetric BMD remained unchanged⁸.

Certificate of Analysis (COA) for Every Batch

A Certificate of Analysis (COA) is a document that verifies a compound’s identity, purity, and batch quality through independent laboratory testing. Every compound from BioLongevity Labs ships with a COA tied to its specific batch, so researchers can confirm exactly what they received before it enters a protocol.

Each COA reports results from third-party laboratory analysis, including:

• High-performance liquid chromatography (HPLC) for purity, typically confirmed at 99% or higher
• Liquid chromatography mass spectrometry (LC-MS) for molecular identity and mass confirmation
• Sterility and endotoxin screening where applicable
• Chemical contaminant and residual solvent checks

COAs are sourced from independent certified labs rather than in-house testing alone, giving researchers a verifiable record of molecular integrity for each batch. All compounds are supplied for research use only.